Close Window

Digital Look Email A Friend

ValiRx signs letter of intent in a bid to fund VAL401

Published by Josh White on 14th January 2020

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

URL: http://www.digitallook.com/dl/news/story/30107164/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.